Dr. Maximilian Autherith and Dr. C. Michael Gibson Discuss: Routine Post-Dilation vs. Conventional Deployment for Balloon-Expandable TAVR: The Randomized DUOTAP Trial November 4, 2026 2026 | Slides | TCT | Trial | Video AutherithDownload Disclosures: TBD Article Navigation Dr. Xianbao Liu and Dr. C. Michael Gibson Discuss: Single vs. Double ProGlide Devices for Access Site Closure After Transfemoral TAVR: The SINGLE-CLOSURE Trial In a complex real world comparison of about 500,000 patients, the addition of Repatha lowered cardiovascular outcomes 20% more than ezetimibe. Dr. Nihar Desai and Dr. C. Michael Gibson discuss the results.
